Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Status:
Recruiting
Trial end date:
2022-10-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MK-8189 at a range of
doses (8 mg, 16 mg, and 24 mg once daily) in adult participants who have an acute episode of
schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition
(DSM-5) criteria. The primary hypotheses are the following: (1) MK-8189 24 mg is superior to
placebo in reducing the Week 6 mean change from baseline in Positive and Negative Syndrome
Scale (PANSS) total score (2) MK-8189 16 mg is superior to placebo in reducing the Week 6
mean change from baseline in PANSS total score